Protagonist Therapeutics
PTGX
127 hedge funds and large institutions have $1.15B invested in Protagonist Therapeutics in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 43 increasing their positions, 40 reducing their positions, and 26 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
31% more capital invested
Capital invested by funds: $875M → $1.15B (+$270M)
8% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 40
1% less funds holding
Funds holding: 128 → 127 (-1)
4% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 26
12.21% less ownership
Funds ownership: 113.41% → 101.2% (-12%)
28% less call options, than puts
Call options by funds: $810K | Put options by funds: $1.12M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$16.6M |
| 2 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
+$11M |
| 3 |
BlackRock
New York
|
+$10.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.93M |
| 5 |
OWP
Obermeyer Wealth Partners
Aspen,
Colorado
|
+$9.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$13.9M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$7.95M |
| 3 |
PA
Perceptive Advisors
New York
|
-$4.1M |
| 4 |
RI
RTW Investments
New York
|
-$3.61M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.61M |
PTGX Hedge Fund Activity: Q1 2021 in Review
127 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2021, worth a combined $1.15B — up 31% from $875M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of PTGX and 25 opened new positions — a net loss of 1 holder — while 40 trimmed existing stakes and 43 added.
The largest buyer was Sofinnova Investments, opening a new position worth an estimated $16.6M. The largest seller was Adage Capital Partners, cutting an estimated $13.9M.
- 127 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2021, down from 128 in Q4 2020.
- Funds reported $1.15B of Protagonist Therapeutics stock for Q1 2021, up 31% quarter-over-quarter.
- 25 funds opened new Protagonist Therapeutics positions in Q1 2021 and 26 closed out, a net change of -1 holder.
- The largest Protagonist Therapeutics buyer in Q1 2021 was Sofinnova Investments, an estimated $16.6M added.
- The largest Protagonist Therapeutics seller in Q1 2021 was Adage Capital Partners, an estimated $13.9M sold.
Based on aggregated 13F filings for Q1 2021.